Standard

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2. / Chen, Sha; Wang, Qian; Christodoulou, Andriana et al.

In: Circulation, Vol. 147, No. 3, 17.01.2023, p. 276-279.

Research output: Contribution to journal › Article › Academic › peer-review

Harvard

Chen, S, Wang, Q, Christodoulou, A, Mylonas, N, Bakker, D, Nederlof, R, Hollmann, MW, Weber, NC, Coronel, R, Wakker, V, Christoffels, VM, Andreadou, I & Zuurbier, CJ 2023, 'Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2', Circulation, vol. 147, no. 3, pp. 276-279. https://doi.org/10.1161/CIRCULATIONAHA.122.061688

APA

Chen, S., Wang, Q., Christodoulou, A., Mylonas, N., Bakker, D., Nederlof, R., Hollmann, M. W., Weber, N. C., Coronel, R., Wakker, V., Christoffels, V. M., Andreadou, I., & Zuurbier, C. J. (2023). Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2. Circulation, 147(3), 276-279. https://doi.org/10.1161/CIRCULATIONAHA.122.061688

Vancouver

Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R et al. Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2. Circulation. 2023 Jan 17;147(3):276-279. doi: 10.1161/CIRCULATIONAHA.122.061688

Author

Chen, Sha ; Wang, Qian ; Christodoulou, Andriana et al. / Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2. In: Circulation. 2023 ; Vol. 147, No. 3. pp. 276-279.

BibTeX

@article{c117b33779e0488696b80374710bcc59,
title = "Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2",
keywords = "body weight, empagliflozin, glucose, infarct size, ischemia/reperfusion, ketones, sodium-glucose cotransporter 2 inhibitor",
author = "Sha Chen and Qian Wang and Andriana Christodoulou and Nikolaos Mylonas and Diane Bakker and Rianne Nederlof and Hollmann, {Markus W.} and Weber, {Nina C.} and Ruben Coronel and Vincent Wakker and Christoffels, {Vincent M.} and Ioanna Andreadou and Zuurbier, {Coert J.}",
note = "Funding Information: Dr Zuurbier received a research grant from Boehringer Ingelheim. The other authors report no conflicts.",
year = "2023",
month = jan,
day = "17",
doi = "10.1161/CIRCULATIONAHA.122.061688",
language = "English",
volume = "147",
pages = "276--279",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

RIS

TY - JOUR

T1 - Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2

AU - Chen, Sha

AU - Wang, Qian

AU - Christodoulou, Andriana

AU - Mylonas, Nikolaos

AU - Bakker, Diane

AU - Nederlof, Rianne

AU - Hollmann, Markus W.

AU - Weber, Nina C.

AU - Coronel, Ruben

AU - Wakker, Vincent

AU - Christoffels, Vincent M.

AU - Andreadou, Ioanna

AU - Zuurbier, Coert J.

N1 - Funding Information: Dr Zuurbier received a research grant from Boehringer Ingelheim. The other authors report no conflicts.

PY - 2023/1/17

Y1 - 2023/1/17

KW - body weight

KW - empagliflozin

KW - glucose

KW - infarct size

KW - ischemia/reperfusion

KW - ketones

KW - sodium-glucose cotransporter 2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85146412278&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.122.061688

DO - 10.1161/CIRCULATIONAHA.122.061688

M3 - Article

C2 - 36649392

VL - 147

SP - 276

EP - 279

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 3

ER -

ID: 31315344